Follistatin is a natural protein that switches off one of the body's own limits on muscle growth. It works by grabbing and neutralising myostatin — a molecule whose whole job is to keep muscles from getting too big2. That mechanism is real and well understood. But the eye-popping "double the muscle" results attached to follistatin come almost entirely from gene therapy and animal studies — not from injecting the peptide, which is what people usually picture. Separating those two is the single most important thing to understand here.
In plain terms: the biology is real; the hype quietly swaps gene therapy and mice for an injection.
What it is
Muscle size is a balance. Some signals tell muscle to grow; myostatin (also called GDF-8) is the main signal telling it to *stop*. Animals and rare humans with broken myostatin genes are famously, visibly over-muscled. Follistatin is the natural counterweight: it binds myostatin — and related molecules called activins — so they cannot deliver their "stop growing" message2.
The protein comes in forms. The gene produces a 344-amino-acid precursor (the origin of the "follistatin-344" / FST-344 label). That is processed into two working isoforms: FST-315, the main form that circulates in blood, and FST-288, which binds tightly to cell surfaces and stays put. In the peptide scene, "follistatin-344" is used as a product name.
In plain terms: myostatin is the muscle brake; follistatin is the thing that jams the brake.
The mechanism — and where the results actually come from
Here is the honest core. When researchers delivered the follistatin gene into muscle using a virus (a technique called gene therapy, which turns the muscle itself into a follistatin factory), the effects were dramatic and lasting.
In a monkey study — cynomolgus macaques — a single injection of an AAV virus carrying the follistatin gene into the quadriceps produced "pronounced and durable" increases in muscle size and strength, without harm to major organs over long-term follow-up1. That is a striking result. But note what it is: gene therapy, in monkeys — the muscle was reprogrammed to keep making follistatin continuously.
That is completely different from injecting a dose of follistatin protein. Recombinant follistatin protein has a short half-life (it is cleared from the blood within hours) and does not linger to keep myostatin suppressed. There are no controlled human trials showing that injected follistatin builds muscle in healthy people.
In plain terms: making the muscle produce follistatin non-stop (gene therapy) is not the same as an injection that clears in hours.
The strongest human data: gene therapy, not the peptide
The furthest follistatin has gone in people is early gene-therapy trials in muscle-wasting disease. A phase 1/2a trial delivered the follistatin gene to the muscles of men with Becker muscular dystrophy; the small study reported some improvement in walking distance in several participants and was used to argue the approach was worth pursuing3. Again: this is gene therapy in patients with a muscle disease — an experimental technology, not an approved treatment, and not an injectable peptide.
Pharmacology at a glance
| Property | Follistatin |
|---|---|
| Class | Natural myostatin/activin-binding protein |
| Target | Binds and neutralises myostatin (GDF-8) and activins |
| Isoforms | FST-344 precursor → FST-315 (circulating) + FST-288 (cell-bound) |
| Injected-protein half-life | Short (cleared within hours) — poor sustained effect |
| Dramatic muscle results | From gene therapy + animal models, not the injected peptide |
| Best human data | Early gene-therapy trials in muscular dystrophy |
| Status | Research compound; not an approved medicine |
What the studies actually found
Read the model column carefully — it is the whole point of this article. The impressive numbers are animal and gene-therapy, not injectable-peptide, results:
| Study | Model / level | What it showed | Year |
|---|---|---|---|
| Rodino-Klapac et al. — review2 | Review (cell + animal) | Framed follistatin as a leading way to inhibit myostatin for muscle disease; explained isoforms and mechanism | 2009 |
| Kota et al.1 | Monkey (gene therapy) | AAV-delivered follistatin gene produced pronounced, durable gains in muscle size and strength | 2009 |
| Mendell et al. — phase 1/2a3 | Human (Becker MD, gene therapy) | Follistatin gene therapy in a small trial reported improved walking distance in several patients | 2015 |
The pattern: real, sometimes dramatic effects — every one of them from gene therapy or animals. The injectable peptide people buy is not what produced these results.
Latest research
- Myostatin inhibition as a field remains active, but the lesson from a decade of drug development is sobering: several pharmaceutical antibodies that block myostatin increased muscle *size* in people without reliably improving *strength or function* — a reminder that bigger muscle on a scan is not the same as a better outcome.
- Follistatin's furthest human step stays gene therapy, not an injectable peptide3; those programmes are small and experimental.
- No controlled human trial supports injected follistatin for muscle building in healthy adults. That absence, next to the gene-therapy headlines, is the honest summary.
The short version
Follistatin is a natural protein that blocks myostatin, the body's muscle-growth brake — a real, well-understood mechanism. But the dramatic muscle-doubling results come from gene therapy and animal studies, and the strongest human data is early gene-therapy work in muscular dystrophy — not the injectable peptide, which clears in hours and has no controlled human muscle-building evidence. It is a research compound, not a medicine, and the gene-therapy hype does not transfer to an injection. Educational overview only, not medical advice. For context, see what are research peptides.